Singapore markets closed

BioCryst Pharmaceuticals, Inc. (BCRX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
13.94-0.26 (-1.80%)
As of 12:11PM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 2.64B
Enterprise value 2.38B
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/sales (ttm)12.75
Price/book (mrq)56.59
Enterprise value/revenue 11.67
Enterprise value/EBITDA -19.09

Trading information

Stock price history

Beta (5Y monthly) 2.05
52-week change 3-1.80%
S&P500 52-week change 3-14.73%
52-week high 319.99
52-week low 37.61
50-day moving average 313.47
200-day moving average 313.11

Share statistics

Avg vol (3-month) 32.59M
Avg vol (10-day) 32.38M
Shares outstanding 5185.94M
Implied shares outstanding 6N/A
Float 8167.68M
% held by insiders 10.97%
% held by institutions 183.13%
Shares short (14 Sept 2022) 428.82M
Short ratio (14 Sept 2022) 413.33
Short % of float (14 Sept 2022) 417.38%
Short % of shares outstanding (14 Sept 2022) 415.50%
Shares short (prior month 14 Aug 2022) 427.35M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)29 Jun 2022


Profit margin -102.96%
Operating margin (ttm)-89.11%

Management effectiveness

Return on assets (ttm)-28.79%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)203.61M
Revenue per share (ttm)1.11
Quarterly revenue growth (yoy)31.20%
Gross profit (ttm)-58.9M
EBITDA -180.39M
Net income avi to common (ttm)-209.64M
Diluted EPS (ttm)-1.07
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)417.48M
Total cash per share (mrq)2.24
Total debt (mrq)630.51M
Total debt/equity (mrq)N/A
Current ratio (mrq)5.19
Book value per share (mrq)-1.15

Cash flow statement

Operating cash flow (ttm)-161.29M
Levered free cash flow (ttm)-145.31M